Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May;29(3):277-290.
doi: 10.1007/s40291-025-00773-x. Epub 2025 Apr 16.

Cell-Free DNA: Features and Attributes Shaping the Next Frontier in Liquid Biopsy

Affiliations
Review

Cell-Free DNA: Features and Attributes Shaping the Next Frontier in Liquid Biopsy

Neeti Swarup et al. Mol Diagn Ther. 2025 May.

Abstract

Cell-free DNA (cfDNA) is changing the face of liquid biopsy as a minimally invasive tool for disease detection and monitoring, with its main applications in oncology and prenatal testing, and rising roles in transplant patient monitoring. However, the processes of cfDNA biogenesis, fragmentation, and clearance are complex and require further investigation. Evidence suggests that cfDNA production relates to mechanisms of cell death and DNA repair, both of which further influence fragment size and its applicability as a biomarker. An emerging domain, cfDNA fragmentomics is being explored for advancing the field of diagnostics using non-mutational signatures such as fragment size ratios and methylation patterns. Thus, this review examines structural diversity in cfDNA with various fragment sizes. In examining these cfDNA subsets, we discuss their distinct biological origins and potential clinical utility. Development of sequencing methodologies has broadened the application of cfDNA in diagnosing cancers and organ-specific pathologies, as well as directing personalized therapies. This has been achieved by identifying and uncovering different subsets of cfDNA in biofluids using different methodologies and biofluids. Different cfDNA subsets provide important insights regarding genomic and epigenetic features, enhancing the understanding of gene regulation, tissue-specific functions, and disease progression. Advancement of these key areas further asserts increasing clinical relevance for the use of cfDNA as a biomarker. Continued exploration of cfDNA subsets is expected to drive further innovation in liquid biopsy and its integration into routine clinical practice.

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding/Acknowledgements: This work was supported by the National Institutes of Health (NIH) (U01 CA233370; UH3 CA206126 and R90 5R90DE031531-03, R21 CA239052, UH2 DE032208, T90DE030860), National Cancer Institute (5K00CA264398-04), American Cancer Society PASD-RSG-23-1142089-01-PASD, Spectrum Solutions 20212918 (DTWW), and JCCC SEED/Ali Jassim Family Cancer Research Fund (Y.K.). In addition, we acknowledge the donation made by Ronnie James Dio Stand Up and Shout Cancer Fund. Conflict of Interest: David Wong, Neeti Swarup, Ho Yeung Leung, Irene Choi, Mohammad Arshad Aziz, and Jordan Cheng declare that they have no conflicts of interest that might be relevant to the contents of this article. Ethics Approval: Not applicable. Consent (Participation and Publication): Not applicable. Author Contributions: N.S., H.Y.L., and I.C. wrote the manuscript. N.S., M.A.A, J.C., and D.T.W.W critically proofread the manuscript. N.S., H.Y.L, I.C, and J.C. performed the literature search and generated all drafts of the figures. Data Availability Statement: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Code Availability: Not applicable.

Figures

Fig. 1
Fig. 1
Plasma derived cfDNA possess different fragment lengths and characteristics. A Low molecular weight DNA extraction with single-stranded DNA library preparation of plasma cfDNA reveals a mononucleosomal cfDNA peak (~166 bps) along with an ultrashort cfDNA peak (40–70 bps) and short cfDNA valley (70–120 bps) (blue box). B Multiples of the nucleosomal peaks (~166 bps, ~320 bps, ~480 bps) are revealed with routine double-stranded library DNA protocols (green box). C Contrasting characteristics of different subsets of cfDNA: Genomic region mapping of called peaks differ amongst subsets of cfDNA; differences in abundance of potential secondary structures seen in cfDNA; differences in end motif cleavage for different subsets of cfDNA. Data derived from [15, 16]. Created in BioRender.com
Fig. 2
Fig. 2
Factors affecting cfDNA characteristics: Processes and structural features that lead to cfDNA formation: biological and cellular processes, genomic structures, nucleosomal associated structures or epigenomic modifications. Source of cfDNA, biofluids, and cells of origin. Created in BioRender.com
Fig. 3
Fig. 3
cfDNA profile in different biofluids using a single-stranded library preparation: A plasma, B saliva and C urine. Data derived from [15, 17, 76]
Fig. 4
Fig. 4
Downstream functions of cfDNA: Immune modulatory effects, horizontal transfer of information and inducing transformation to cancer phenotype, biofilm formation. Created in BioRender.com
Fig. 5
Fig. 5
Different technical considerations that affect cfDNA attributes. Created in BioRender.com

References

    1. de Miranda FS, Barauna VG, Dos Santos L, Costa G, Vassallo PF, Campos LCG. Properties and application of cell-free DNA as a clinical biomarker. Int J Mol Sci. 2021;22(17):9110. - DOI - PMC - PubMed
    1. Grabuschnig S, Bronkhorst AJ, Holdenrieder S, Rosales Rodriguez I, Schliep KP, Schwendenwein D, et al. Putative origins of cell-free DNA in humans: a review of active and passive nucleic acid release mechanisms. Int J Mol Sci. 2020;21(21):8062. - DOI - PMC - PubMed
    1. Liskova A, Samec M, Koklesova L, Giordano FA, Kubatka P, Golubnitschaja O. Liquid biopsy is instrumental for 3PM dimensional solutions in cancer management. J Clin Med. 2020;9:2749. - DOI - PMC - PubMed
    1. Batool SM, Yekula A, Khanna P, Hsia T, Gamblin AS, Ekanayake E, et al. The Liquid Biopsy Consortium: challenges and opportunities for early cancer detection and monitoring. Cell Rep Med. 2023;4: 101198. - DOI - PMC - PubMed
    1. Cheng JC, Swarup N, Wong DTW, Chia D. A review on the impact of single-stranded library preparation on plasma cell-free diversity for cancer detection. Front Oncol. 2024;14:1332004. - DOI - PMC - PubMed

LinkOut - more resources